Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00182754 · ClinicalTrials.gov registry record · Phase 3
Octreotide in Treating Patients With Cancer-Related Malignant Ascites
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 33
- Enrollment target
NCT00182754 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 33 participants.
The verdict
NCT00182754, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 33 participants
- Enrollment target
Study Summary
RATIONALE: Octreotide may be an effective treatment for malignant ascites. It is not yet known whether octreotide is more effective than a placebo in treating malignant ascites. PURPOSE: This randomized phase III trial is studying octreotide to see how well it works compared to placebo in treating patients with cancer-related malignant ascites.
Interventions
- OTHER placebo
- DRUG octreotide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2005-10 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00182754
The ClinicalTrials.gov registry entry for NCT00182754 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00182754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00182754 about?
NCT00182754 is a clinical study titled "Octreotide in Treating Patients With Cancer-Related Malignant Ascites". RATIONALE: Octreotide may be an effective treatment for malignant ascites. It is not yet known whether octreotide is more effective than a placebo in treating malignant ascites. PURPOSE: This randomized phase III trial is studying octreotide to see how well it works compared to placebo in treating ...
What is the current status of trial NCT00182754?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 33 participants. The study started on 2005-10. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00182754?
The interventions under investigation include: placebo (OTHER), octreotide acetate (DRUG).
Who is sponsoring clinical trial NCT00182754?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.